Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

VMD asserts safety of Leptospira vaccine
Vets are reminded to tailor vaccination programmes for specific animals.
Statement follows reports of adverse events from vaccinated dogs.

The Veterinary Medicines Directorate (VMD) has reaffirmed the safety of the Leptospira vaccine, after adverse events were reported for L2 and L4 vaccines.

The statement comes amidst media reports and social media post which raised concerns amidst adverse events in vaccinated dogs.

There are several Leptospira vaccines authorised for use in the UK that either contain two strains (L2) or four strains (L4) of Leptospira bacteria. The VMD says that the overall incidence of adverse events remains rare, and therefore its benefits outweigh its risks.

In its latest analysis of adverse events in L2 vaccine products, the VMD says that incidence of adverse events combined was 0.016 per cent. Meanwhile, for L4 vaccine products, this figure was 0.040 per cent.

This means that, for every 10,000 estimated animals treated, the VMD has received fewer than two adverse events for L2 and fewer than four adverse events for L4.

The VMD’s data for adverse events involving death, including euthanasia, was similarly low. For all L2 vaccine products the percentage was at 0.0017 per cent, while for L4 vaccine products it was 0.0033 per cent.

The VMD says that, therefore, incidence of adverse effects was rare and those involving death was very rare.

There has also been concern from the veterinary industry and members of the public that some Leptospira vaccines are being withdrawn from the market. While the VMD says it cannot prevent such occurrences, it is reassuring pet owners that both L2 and L4 Leptospira vaccines remain available.

Veterinary surgeons are being reminded to tailor vaccination programmes for each individual animal. These programmes should be informed by the local disease risk, as well as other potential risks that will be listed in the Summary of Product Characteristics and product information.

Image © Maria Sbytova/Shutterstock.com

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.